Skip to main content
Retour
SGIPF logo

Sugi Holdings Co.,Ltd.

Qualité des données : 100%
Suracheté
SGIPF
OTC Healthcare Medical - Pharmaceuticals
16,29 €
0,00 € (0,00%)
Cap. Boursière : 2,95B
Fourchette du Jour
16,29 € 16,29 €
Fourchette 52 Semaines
16,29 € 16,29 €
Volume
100
Moyenne 50J / 200J
16,29 € / 16,29 €
Clôture Précédente
16,29 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (626 pairs)

Métrique Action Médiane du Secteur
P/E 0,1 0,4
P/B 0,0 2,9
ROE % 10,6 3,7
Net Margin % 2,9 3,8
Rev Growth 5Y % 252,9 10,0
D/E 0,2 0,2

Points Clés

Revenue grew 252,94% annually over 5 years — strong growth
Earnings grew 16,88% over the past year
ROE of 10,61% — decent returns on equity
Debt/Equity of 0,18 — conservative balance sheet
Generating 10,91B in free cash flow
P/E of 0,11 — trading at a low valuation

Croissance

Revenue Growth (5Y)
252,94%
Revenue (1Y)17,94%
Earnings (1Y)16,88%
FCF Growth (3Y)841,45%

Qualité

Return on Equity
10,61%
ROIC10,78%
Net Margin2,93%
Op. Margin4,85%

Sécurité

Debt / Equity
0,18
Current Ratio1,14
Interest Coverage187,50

Valorisation

P/E Ratio
0,11
P/B Ratio0,01
EV/EBITDA-0,11
Dividend Yield0,01%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 17,94% Revenue Growth (3Y) 1238,72%
Earnings Growth (1Y) 16,88% Earnings Growth (3Y) 1257,15%
Revenue Growth (5Y) 252,94% Earnings Growth (5Y) 237,40%
Profitability
Revenue (TTM) 878,02B Net Income (TTM) 25,69B
ROE 10,61% ROA 5,19%
Gross Margin 31,33% Operating Margin 4,85%
Net Margin 2,93% Free Cash Flow (TTM) 10,91B
ROIC 10,78% FCF Growth (3Y) 841,45%
Safety
Debt / Equity 0,18 Current Ratio 1,14
Interest Coverage 187,50 Dividend Yield 0,01%
Valuation
P/E Ratio 0,11 P/B Ratio 0,01
P/S Ratio 0,00 PEG Ratio 1,02
EV/EBITDA -0,11 Dividend Yield 0,01%
Market Cap 2,95B Enterprise Value -4,49B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 878,02B 744,48B 4,90B 5,44B 5,66B
Net Income 25,69B 21,98B 139,47M 168,61M 198,24M
EPS (Diluted) 141,96 121,46 0,77 0,91 1,07
Gross Profit 275,04B 228,84B 1,49B 1,67B 1,70B
Operating Income 42,56B 36,62B 232,31M 279,46M 319,51M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 495,12B 390,56B 2,59B 2,93B 3,27B
Total Liabilities 244,41B 157,20B 1,00B 1,07B 1,38B
Shareholders' Equity 250,70B 233,36B 1,59B 1,86B 1,88B
Total Debt 45,35B 837,00M 14,34M 20,05M 21,88M
Cash & Equivalents 52,79B 43,43B 254,06M 294,19M 524,17M
Current Assets 246,48B 199,05B 1,47B 1,67B 2,01B
Current Liabilities 216,08B 136,65B 858,66M 891,91M 1,21B

Scores de Stratégies

This stock passed the criteria for 3 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#180 of 820
58
Growth Price/Sales Ratio Focus (Ken Fisher)
#240 of 616
42
Value Defensive Investing (Benjamin Graham)
#393 of 708
25

Activité Récente

Entré Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entré Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Entré Defensive Investing (Benjamin Graham)
Mar 24, 2026